ABIVAX Société Anonyme
ENXTPAABVX entered June with what should have been its finest hour. The Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis met its primary endpoint. Instead, shares closed at €63.10 on June 2 — down 43.6% on the day and 42.5% on the week — as safety data showing cancer cases in the treatment arm overwhelmed the efficacy headline. The market reaction was swift and…
Snapshot as of 3 Jun 2026
ABVX entered June with what should have been its finest hour. The Phase 3 ABTECT maintenance trial for obefazimod in ulcerative colitis met its primary endpoint. Instead, shares closed at €63.10 on June 2 — down 43.6%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ABVX — free to start on ORTEX.
Sign up for free →Open ABVX on ORTEX